PRAME peptide-Major histocompatibility complex class I complex (PRAME-MHC complex)

The PRAME-MHC complex is a molecular entity formed when peptides derived from the PRAME protein, a cancer/testis antigen, bind to major histocompatibility complex class I (MHC I) molecules on the surface of cells. This allows immune cells, such as cytotoxic T lymphocytes, to recognize and potentially destroy tumor cells presenting PRAME peptides. Targeting this complex with TCR-mimic antibodies, engineered T cells, or cancer vaccines is a promising therapeutic strategy in cancers with high PRAME expression, and the presence of PRAME peptide-MHC complexes serves as a biomarker and determinant for patient selection[4][5][6]. Potential therapeutic challenges include immune escape due to PRAME loss and risk of autoimmunity or adverse immune reactions.

Other names

PRAME/HLA-A2 complexPRAME peptide-MHC complexPRAME antigen presentation complexPRAME epitope-MHC complex

Recognition and killing of tumor cells by cytotoxic T lymphocytes (CTLs) targeting PRAME-presenting cells; Antibody-mediated cytotoxicity via PRAME peptide-MHC recognition